

## DAFTAR PUSTAKA

- Abdelmalak, J., Tan, N., Con, D., Eslick, G., Majeed, A., Kemp, W., & Roberts, S. K. (2023). The Effect of Aspirin Use on Incident Hepatocellular Carcinoma-An Updated Systematic Review and Meta-Analysis. *Cancers*, 15(13), 3518.
- Abubakar, A. R., Chedi, B. A., Mohammed, K. G., and Haque, M. (2015). Drug interaction and its implication in clinical practice and personalized medicine. *National Journal of Physiology, Pharmacy and Pharmacology*, 5(5), 343-349. <http://dx.doi.org/10.5455/njppp.2015.5.2005201557>
- Amalia, M., Hidayati, P. H., Yanti, A. K. E., Vitayani, S., & Gayatri, S. W. (2023). Karakteristik Pasien Sirosis Hepatis. *UMI Medical Journal*, 8(1), 53-61.
- Azmi, F. (2016). Anatomi dan Histologi Hepar. *JURNAL KEDOKTERAN*, 1(2), 147-154. Retrieved from <https://e-journal.unizar.ac.id/index.php/kedokteran/article/view/595>
- Baiges, A., & Hernández-Gea, V. (2022). Management of Liver Decompensation in Advanced Chronic Liver Disease: Ascites, Hyponatremia, and Gastroesophageal Variceal Bleeding. *Clinical drug investigation*, 42(Suppl 1), 25–31. <https://doi.org/10.1007/s40261-022-01147-5>
- Cahyaningsih, I., & Wicaksono, W. A. (2020). Penilaian Risiko Interaksi Obat pada Pasien dengan Diabetes Melitus Tipe 2. *Indonesian Journal of Clinical Pharmacy*, 9(1), 9-17.
- Chen, Y. C., Li, Y. D., Lu, C. M., Huang, W. C., Kao, S. S., & Chen, W. C. (2022). Propranolol use in patients with cirrhosis and refractory ascites: A nationwide study. *Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association*, 28(2), 108–114. [https://doi.org/10.4103/sjg.sjg\\_586\\_21](https://doi.org/10.4103/sjg.sjg_586_21)
- Corrie, K., and Hardman, J. G. (2011). Mechanisms of drug interactions: pharmacodynamics and pharmacokinetics. *Anaesthesia and Intensive Care Medicine*, 12(4), 156-159. <https://doi.org/10.1016/j.mpaic.2010.12.008>
- Dasopang, E. S., Harahap, U., & Lindarto, D. (2015). Polifarmasi dan interaksi obat pasien usia lanjut rawat jalan dengan penyakit metabolik. *Indonesian Journal of Clinical Pharmacy*, 4(4), 235-241.
- Dipiro, J.T., Chisholm-Burns M.A., & Schwinghammer T.L., & Malone P.M., & Kolesar J.M., & Lee K.C., & Bookstaver P(Eds.), (2019). *Pharmacotherapy Principles and Practice, 5e*. McGraw Hill : New York.

- Dinas kesehatan banten. (2018). Profil kesehatan banten tahun 2018. Diakses 10 Desember 2023. <https://dinkes.bantenprov.go.id/pages/fdaf7373-86e2-43bd-8554-8250bc99dade/profil-kesehatan-provinsi-banten-tahun-2018>
- Drugs.com. (2024). Drug Interaction Checker. [https://www.drugs.com/interaction/list/?drug\\_list=](https://www.drugs.com/interaction/list/?drug_list=) [Diakses pada 29 Mei 2024]
- Dwyer, J.P., Jayasekera, C. and Nicoll, A. (2014), Analgesia in cirrhosis. *J Gastroenterol Hepatol*, 29: 1356-1360. <https://doi.org/10.1111/jgh.12560>
- Elzouki, A. N., Zahid, M., Akbar, R. A., Alfitori, G. B., Purayil, S. C., Imanullah, R., & Danjuma, M. I. (2020). Polypharmacy and drug interactions amongst cirrhotic patients discharged from a tertiary center: results from a national quality improvement audit. *Arab Journal of Gastroenterology*, 21(4), 216-218.
- European Association for the Study of the Liver. (2018). EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *Journal of hepatology*, 69(2), 406-460. <https://doi.org/10.1016/j.jhep.2018.03.024>
- Fery. (2016). Penyakit Wilson : Diagnosis dan Tatalaksana. *Cermin Dunia Kedokteran*, 43(7), 495-499, doi:10.55175/cdk.v43i7.78.
- Fitriyanti, F., & Marthilia, M. D. (2022). Gambaran Profil Pengobatan dan Analisis Potensi Interaksi Obat pada Pasien DMG dengan Penyakit Penyerta pada Pelayanan Kesehatan Kota Samarinda. *Borneo Studies and Research*, 3(2), 2190-2199.
- Geller, S. A., & de Campos, F. P. (2015). Hereditary hemochromatosis. *Autopsy & case reports*, 5(1), 7–10. <https://doi.org/10.4322/acr.2014.043>
- Gerber, W., Steyn, J. D., Kotzé, A. F., and Hamman, J. H. (2018). Beneficial pharmacokinetic drug interactions: a tool to improve the bioavailability of poorly permeable drugs. *Pharmaceutics*, 10(3), 106. <https://doi.org/10.3390/pharmaceutics10030106>
- Geong, G. Y., Kang, S. H., & Lee, C. M. (2019). An updated review on the epidemiology, pathophysiology, etiology and diagnosis of liver cirrhosis. <https://www.researchgate.net/publication/331752269>
- Gitawati, R. (2008). Interaksi obat dan beberapa implikasinya. *Media Penelitian dan Pengembangan Kesehatan*, 18(4).

- Global Burden Of Disease. (2019). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 396, 1204–1222
- Hakim, L. N. (2020). Urgensi revisi undang-undang tentang kesejahteraan lanjut usia. *Aspirasi: Jurnal Masalah-Masalah Sosial*. 11(1)
- Hambley, B. C., Diamond, A., Connie, S., Partovi, S., Smith, T., & LoPresti, C. (2016). Effect of vitamin K on coagulopathy of liver disease: a single center retrospective review. *Blood*, 128(22), 2583.
- Hasnain H, Ali H, Zafar F, Akbar AS, Hameed K, Shareef H, Mallick N, Tariq A, Fatima R. (2017). Drug-Drug Interaction: Facts And Comparisons With National And International Bench Marks: A Threat More Than A Challenge For Patient Safety In Clinical And Economic Scenario. *Professional Med J* 2017;24(3):357-365. DOI: 10.17957/TPMJ/17.3670
- Juweriya Farooq, M.M. Sana, P.M. Chetana, Mansour Almuqbil, et al. (2023). Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life. *Saudi Pharmaceutical Journal*. 3(8). <https://doi.org/10.1016/j.jsps.2023.06.001>.
- Kamimura, K., Sakamaki, A., Kamimura, H., Setsu, T., Yokoo, T., Takamura, M., & Terai, S. (2019). Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. *World journal of gastroenterology*, 25(15), 1817.
- Kementerian Kesehatan RI Direktorat Pencegahan Dan Pengendalian Penyakit Menular. (2022) Laporan kinerja 2022. Jakarta. <https://p2pm.kemkes.go.id/storage/informasi-publik/content/GHwE3BiLbOrvZZPKY1Pm91BIRWqzE4-metaTGFwa2luIFAyUE0gMjAyMi5wZGY=-.pdf>
- Khoshbaten, M., Aliasgarzadeh, A., Masnadi, K., Tarzamani, M. K., Farhang, S., Babaei, H., Kiani, J., Zaare, M., & Najafipoor, F. (2010). N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease. *Hepatitis monthly*, 10(1), 12–16
- Kusuma, I. Y., Megasari, P. O. D., & Sukiatno, L. (2018). Identifikasi potensi interaksi obat pada pasien hipertensi: studi retrospektif resep polifarmasi di Apotek Karya Sehat Purwokerto. *Viva Medika: Jurnal Kesehatan, Kebidanan dan Keperawatan*, 12(1), 72-80.
- Lovena, A., Miro, S., & Efrida, E. (2017). Karakteristik Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*, 6(1), 5-12.

- Marrero JA, Kudo M, Venook AP, Ye S-L, Jean-, Bronowicki P, et al. (2016) Observational Registry of Sorafenib Use in Clinical Practice Across Child-Pugh SSubgroups: The GIDEON Study. *J Hepatol*, 1–33
- Martini, F. H., Nath, J. L., & Bartholomew, E. F. (2018). *Fundamentals of Anatomy and Physiology Ninth Edition*. San Francisco: Pearson Education.
- Mukherjee S, Patel P, John S. (2024). Laktulosa. StatPearls. National Center Of Biotechnology Information: <https://www.ncbi.nlm.nih.gov/books/NBK536930/> [Diakses pada 7 Juni 2024]
- Muti, A. F., & Anindya, C. (2022). Analysis of Potential Drug-drug Interactions in Liver Cirrhosis Patients. *Galenika Journal of Pharmacy*, 7(1), 17-28
- National Center of Biotechnology Information. (2022). Sirosis Hati. Terdapat di : <https://www.ncbi.nlm.nih.gov/books/NBK482419/> [Diakses pada 12 Oktober 2023]
- National Institute of Diabetes and Digestive and Kidney. (2023). <https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis> [Diakses pada 22 november 2023]
- National Institutes of Health. (2024). Kapsul Ketoprofen. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=51f3222f-bc05-4117-881d-85880b092e42&type=display> [Diakses pada 16/06/2024]
- Ndraha, Suzanna., Imelda, I., Tendean, M., & Santoso, M. (2018). Komplikasi Penderita Sirosis Hati Di RSUD KOJA Pada Bulan Juli-November 2017. *Jurnal Kedokteran Meditek*
- Nessa, M. L., Yusuf, F., & Mudatsir, M. (2017). Hubungan Child Pugh Score dengan Kualitas Hidup pada Pasien Sirosis Hati di Bagian Penyakit Dalam RSUDZA Banda Aceh. *Jurnal Ilmiah Mahasiswa Kedokteran Biomedis*, 2(4).
- Niu, J., Straubinger, RM, & Mager, DE (2019). Interaksi Obat-Obat Farmakodinamik. *Farmakologi dan terapi klinis* , 105 (6), 1395–1406. <https://doi.org/10.1002/cpt.1434>
- Parulian, L., Listyanti, E., Hati, A. K., & Sunnah, I. 2019. Analisis Hubungan Polifarmasi Dan Interaksi Obat Pada Pasien Rawat Jalan Yang Mendapat Obat Hipertensi Di Rsp. Dr. Ario Wirawan Periode JanuariMaret 2019. *Indonesian Journal of Pharmacy and Natural Product*, 2(2)

- Ramatillah, L.D. (2022). Buku Ajar Interaksi Obat. Universitas 17 Agustus 1945. Jakarta
- Robert L, T. G., et al. (2022). Findings from a Nationwide Study on Alcohol Consumption Patterns in an Upper Middle-Income Country. *International journal of environmental research and public health*, 19(14), 8851. <https://doi.org/10.3390/ijerph19148851>
- Romadhoni, N., Indria, D. M., & Wibisono, N. (2023). Hubungan Polifarmasi dengan Potensi dan Tingkat Keparahan Interaksi Obat pada Resep Antihipertensi di Krims. *Jurnal Bio Komplementer Medicine*, 10(1).
- Sari, Y. O., Lusia, D. A., & Almasdy, D. (2023). Kajian Potensi Interaksi Obat pada Pasien Rawat Jalan dengan Polifarmasi di RSUD HAMBATA Batang Hari Tahun 2020. *Menara Ilmu: Jurnal Penelitian dan Kajian Ilmiah*, 17(1).
- Sherwood L. (2013). *Introduction to Human physiology*. 8th ed. Cengage Learning
- Silaban, B. P., Lumongga, F., & Silitonga, H. (2020). Karakteristik Penderita Sirosis Hati. *Jurnal Kedokteran Methodist*, 13(2), 85-91.
- Solang, N. G., Wiyono, W., & Mpila, D. A. (2021). Identifikasi interaksi obat potensial pada pasien stroke rawat inap di rsup prof. Dr. Rd kandou manado. *Pharmacon*, 10(1), 639-648.
- Sugiyono. (2017). *Metode Penelitian Kuantitatif, Kualitatif, dan R&D*. Bandung: Alfabeta.
- Smith, A., Baumgartner, K., & Bositis, C. (2019). Cirrhosis: diagnosis and management. *American family physician*, 100(12), 759-770.
- Triananda, R. P., dan Yuswar, M. A. (2017). Pola Penggunaan Obat-Obatan pada Pasien Sirosis Hati Rawat Inap RSUD dr. Soedarso Pontianak. *Jurnal Mahasiswa Farmasi Fakultas Kedokteran UNTAN*, 4(1).
- Vijayan M, A AK, Selina ASK, R RP. (2014). Clinical Profile and Prescribing Pattern of Cirrhosis in a Tertiary Care Hospital. *Indian J Pharm Pract*. 7(3):69–74.
- Wiranata, I. M., Hasmono, D., & Surdijati, S. (2019). Studi penggunaan omeprazole pada pasien sirosis hati dengan Hemetamesis Melena Rawat Inap di RSUD Kabupaten Sidoarjo. *Jurnal Farmasi Sains dan Terapan (Journal of Pharmacy Science and Practice)*, 4(1), 36-43.
- Zhou, W. C., Zhang, Q. B., & Qiao, L. (2014). Pathogenesis of liver cirrhosis. *World journal of gastroenterology*, 20(23), 7312–7324. <https://doi.org/10.3748/wjg.v20.i23.7312>
- Zoratti, C., Moretti, R., Rebuzzi, L., Albergati, I. V., Di Somma, A., Decorti, G., Di Bella, S., Crocè, L. S., & Giuffrè, M. (2021). Antibiotics and Liver

Cirrhosis: What the Physicians Need to Know. *Antibiotics* (Basel, Switzerland), 11(1), 31. <https://doi.org/10.3390/antibiotics11010031>